FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186455232> ?p ?o ?g. }

• W3186455232 endingPage "326" @default.
• W3186455232 startingPage "321" @default.
• W3186455232 abstract "In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). This post hoc analysis of PALOMA-2 evaluated the efficacy and safety of palbociclib plus letrozole in patients with preexisting conditions grouped by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC).Postmenopausal patients without prior treatment for ABC were randomized 2:1 to receive palbociclib (125 mg/d on a 3 weeks on/1 week off schedule) plus letrozole (2.5 mg/d, continuous) or placebo plus letrozole. Patients were grouped by the following MedDRA SOC preexisting conditions: gastrointestinal, musculoskeletal, metabolic, and vascular/cardiac. Median PFS was estimated by the Kaplan-Meier method, and treatment emergent adverse events (AEs) were compared between treatment arms within each preexisting condition subgroup.At baseline, 276 (41.4 %) patients had preexisting gastrointestinal disorders, 390 (58.6 %) had musculoskeletal disorders, 259 (38.9 %) had metabolic disorders, and 382 (57.4 %) had vascular/cardiac disorders. Baseline characteristics were similar between subgroups and between each arm within subgroups. Regardless of baseline preexisting condition, palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole. Treatment-emergent AEs associated with palbociclib plus letrozole and dose modifications due to AEs were similar across preexisting condition subgroups.This post hoc analysis of PALOMA-2 demonstrated a favorable effect of palbociclib on PFS and a safety profile consistent with previous observations, regardless of underlying preexisting condition. Pfizer Inc (NCT01740427)." @default.
• W3186455232 created "2021-08-02" @default.
• W3186455232 creator A5000862048 @default.
• W3186455232 creator A5007579054 @default.
• W3186455232 creator A5009694312 @default.
• W3186455232 creator A5010886287 @default.
• W3186455232 creator A5030689616 @default.
• W3186455232 creator A5061176953 @default.
• W3186455232 creator A5067468792 @default.
• W3186455232 creator A5072563567 @default.
• W3186455232 creator A5078251366 @default.
• W3186455232 creator A5086054339 @default.
• W3186455232 creator A5090337589 @default.
• W3186455232 date "2021-10-01" @default.
• W3186455232 modified "2023-10-18" @default.
• W3186455232 title "Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2" @default.
• W3186455232 cites W1966571450 @default.
• W3186455232 cites W2092364303 @default.
• W3186455232 cites W2134822987 @default.
• W3186455232 cites W2145412622 @default.
• W3186455232 cites W2158229692 @default.
• W3186455232 cites W2277431766 @default.
• W3186455232 cites W2552099557 @default.
• W3186455232 cites W2614823801 @default.
• W3186455232 cites W2883737490 @default.
• W3186455232 cites W2908699784 @default.
• W3186455232 cites W2930378888 @default.
• W3186455232 cites W3123647779 @default.
• W3186455232 doi "https://doi.org/10.1016/j.breast.2021.07.017" @default.
• W3186455232 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8361185" @default.
• W3186455232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34388698" @default.
• W3186455232 hasPublicationYear "2021" @default.
• W3186455232 type Work @default.
• W3186455232 sameAs 3186455232 @default.
• W3186455232 citedByCount "7" @default.
• W3186455232 countsByYear W31864552322022 @default.
• W3186455232 countsByYear W31864552322023 @default.
• W3186455232 crossrefType "journal-article" @default.
• W3186455232 hasAuthorship W3186455232A5000862048 @default.
• W3186455232 hasAuthorship W3186455232A5007579054 @default.
• W3186455232 hasAuthorship W3186455232A5009694312 @default.
• W3186455232 hasAuthorship W3186455232A5010886287 @default.
• W3186455232 hasAuthorship W3186455232A5030689616 @default.
• W3186455232 hasAuthorship W3186455232A5061176953 @default.
• W3186455232 hasAuthorship W3186455232A5067468792 @default.
• W3186455232 hasAuthorship W3186455232A5072563567 @default.
• W3186455232 hasAuthorship W3186455232A5078251366 @default.
• W3186455232 hasAuthorship W3186455232A5086054339 @default.
• W3186455232 hasAuthorship W3186455232A5090337589 @default.
• W3186455232 hasBestOaLocation W31864552321 @default.
• W3186455232 hasConcept C121608353 @default.
• W3186455232 hasConcept C126322002 @default.
• W3186455232 hasConcept C142724271 @default.
• W3186455232 hasConcept C143998085 @default.
• W3186455232 hasConcept C197934379 @default.
• W3186455232 hasConcept C204787440 @default.
• W3186455232 hasConcept C27081682 @default.
• W3186455232 hasConcept C2775930923 @default.
• W3186455232 hasConcept C2776166826 @default.
• W3186455232 hasConcept C2777793932 @default.
• W3186455232 hasConcept C2778812593 @default.
• W3186455232 hasConcept C2779744173 @default.
• W3186455232 hasConcept C2780482068 @default.
• W3186455232 hasConcept C530470458 @default.
• W3186455232 hasConcept C67761136 @default.
• W3186455232 hasConcept C71924100 @default.
• W3186455232 hasConcept C84606932 @default.
• W3186455232 hasConceptScore W3186455232C121608353 @default.
• W3186455232 hasConceptScore W3186455232C126322002 @default.
• W3186455232 hasConceptScore W3186455232C142724271 @default.
• W3186455232 hasConceptScore W3186455232C143998085 @default.
• W3186455232 hasConceptScore W3186455232C197934379 @default.
• W3186455232 hasConceptScore W3186455232C204787440 @default.
• W3186455232 hasConceptScore W3186455232C27081682 @default.
• W3186455232 hasConceptScore W3186455232C2775930923 @default.
• W3186455232 hasConceptScore W3186455232C2776166826 @default.
• W3186455232 hasConceptScore W3186455232C2777793932 @default.
• W3186455232 hasConceptScore W3186455232C2778812593 @default.
• W3186455232 hasConceptScore W3186455232C2779744173 @default.
• W3186455232 hasConceptScore W3186455232C2780482068 @default.
• W3186455232 hasConceptScore W3186455232C530470458 @default.
• W3186455232 hasConceptScore W3186455232C67761136 @default.
• W3186455232 hasConceptScore W3186455232C71924100 @default.
• W3186455232 hasConceptScore W3186455232C84606932 @default.
• W3186455232 hasLocation W31864552321 @default.
• W3186455232 hasLocation W31864552322 @default.
• W3186455232 hasLocation W31864552323 @default.
• W3186455232 hasLocation W31864552324 @default.
• W3186455232 hasOpenAccess W3186455232 @default.
• W3186455232 hasPrimaryLocation W31864552321 @default.
• W3186455232 hasRelatedWork W2610563129 @default.
• W3186455232 hasRelatedWork W2740803632 @default.
• W3186455232 hasRelatedWork W2751810360 @default.
• W3186455232 hasRelatedWork W2924345863 @default.
• W3186455232 hasRelatedWork W2931385471 @default.
• W3186455232 hasRelatedWork W2943438364 @default.
• W3186455232 hasRelatedWork W3203106735 @default.
• W3186455232 hasRelatedWork W3203690439 @default.

• next